In the 2022 edition of the WHO classification for RCC, this class of renal medullary carcinoma (RMC) with mutations in the SMARCB1 gene is classified as a new molecular category called SMARCB1-deficient RMC [5]. This evidence concerns the gene SMARCB1 and renal cell carcinoma.